Publications by authors named "Philip C Caron"

TP53-mutant mantle cell lymphoma (MCL) is associated with poor survival outcomes with standard chemoimmunotherapy. Dual BTK and BCL2-inhibition with or without anti-CD20 monoclonal antibody therapy has shown promising activity in TP53-mutant MCL. We conducted a multi-center phase 2 study of zanubrutinib, obinutuzumab, and venetoclax (BOVen) in untreated MCL patients with TP53 mutation.

View Article and Find Full Text PDF
Article Synopsis
  • The combination of rituximab and lenalidomide (R-len) is an effective treatment for relapsed/refractory indolent non-Hodgkin lymphoma (iNHL), specifically for follicular lymphoma (FL) and marginal zone lymphoma (MZL), with a significant overall response rate of 82%.
  • In a study involving 84 patients, the median age at treatment initiation was 65, with a median progression-free survival of 22 months and a 2-year overall survival rate of 83%.
  • Common adverse effects included hematologic toxicity, fatigue, and gastrointestinal issues, but overall safety aligned with previous clinical trials, suggesting R-len’s use in real-life settings is consistent with
View Article and Find Full Text PDF

Nodal marginal zone lymphoma (NMZL) is a rare non-Hodgkin B-cell lymphoma that has historically been difficult to define, though is now formally recognized by the World Health Organization Classification. To better characterize the clinical outcomes of patients with NMZL, we reviewed a sequential cohort of 187 patients with NMZL to describe baseline characteristics, survival outcomes, and time-to-event data. Initial management strategies were classified into five categories: observation, radiation, anti-CD20 monoclonal antibody therapy, chemoimmunotherapy, or other.

View Article and Find Full Text PDF

Nodal peripheral T-cell lymphomas (PTCL), the most common PTCLs, are generally treated with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP)-based curative-intent chemotherapy. Recent molecular data have assisted in prognosticating these PTCLs, but most reports lack detailed baseline clinical characteristics and treatment courses. We retrospectively evaluated cases of PTCL treated with CHOP-based chemotherapy that had tumors sequenced by the Memorial Sloan Kettering Integrated Mutational Profiling of Actionable Cancer Targets next-generation sequencing panel to identify variables correlating with inferior survival.

View Article and Find Full Text PDF

Between 1998 and 2009, a total of 295 patients (median age 58, 53% females) with newly diagnosed early-stage follicular lymphoma (FL) were managed at Memorial Sloan Kettering Cancer Center. Approximately half of patients (137, 46%) underwent initial observation and half (158, 54%) immediate treatment: radiation alone (n = 108), systemic treatment alone (n = 29), or combined modality treatment (n = 21). Median follow-up was 8.

View Article and Find Full Text PDF

Diffuse large B-cell lymphoma (DLBCL) predominantly affects older adults with suboptimal therapeutic outcomes due to increased treatment-related mortality and toxicities in vulnerable patients, clinically defined by geriatric impairments such as functional limitation, multimorbidity, or cognitive deficits. In this prospective pilot study, we evaluated a rituximab/prednisone prephase treatment strategy in 33 older, vulnerable patients with newly diagnosed DLBCL, defined by either age ≥70 years or age 60-70 years with Karnofsky performance scale (KPS) <80. A single dose of rituximab 375 mg/m2 between 3-10 days and oral prednisone for at least 5 days prior to the first dose of chemoimmunotherapy was administered.

View Article and Find Full Text PDF

Although methotrexate (MTX) is the most widely used therapy for central nervous system (CNS) prophylaxis in patients with diffuse large B-cell lymphoma (DLBCL), the optimal regimen remains unclear. We examined the efficacy of different prophylactic regimens in 585 patients with newly diagnosed DLBCL and high-risk for CNS relapse, treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) or R-CHOP-like regimens from 2001 to 2017, of whom 295 (50%) received prophylaxis. Intrathecal (IT) MTX was given to 253 (86%) and high-dose MTX (HD-MTX) to 42 (14%).

View Article and Find Full Text PDF
Article Synopsis
  • * Overall survival and disease-free survival rates after 10 years were both 77%; however, extranodal involvement was linked to worse outcomes compared to nodal involvement, indicating a hazard ratio of 3.44 for overall survival.
  • * The study found that consolidating radiation therapy (RT) improved outcomes for patients with extranodal involvement, but this benefit diminished for those who were PET negative after treatment, with relapses primarily occurring
View Article and Find Full Text PDF
Article Synopsis
  • Follicular lymphoma (FL) patients often receive multiple treatments, but survival rates after different lines of treatment are not well understood in the era post-rituximab.
  • A study of 1,088 FL patients found that while median overall survival (OS) after first-line treatment was undetermined, median progression-free survival (PFS) was about 4.73 years, with survival declining significantly after successive treatments.
  • The study also revealed that an increase in the Follicular Lymphoma International Prognostic Index (FLIPI) score after an initial observation period indicates poorer survival outcomes, emphasizing the need for new treatments for recurrent cases.
View Article and Find Full Text PDF

Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is a rare subtype of lymphoma that, like other Hodgkin lymphomas, has historically been treated aggressively. However, in most cases, NLPHL has an indolent course, which raises the question of to what extent these patients require aggressive upfront treatment. We describe the management and outcomes of consecutive NLPHL patients diagnosed at Memorial Sloan Kettering Cancer Center (MSK), with a focus on evaluating active surveillance.

View Article and Find Full Text PDF

A PHP Error was encountered

Severity: Notice

Message: fwrite(): Write of 34 bytes failed with errno=28 No space left on device

Filename: drivers/Session_files_driver.php

Line Number: 272

Backtrace:

A PHP Error was encountered

Severity: Warning

Message: session_write_close(): Failed to write session data using user defined save handler. (session.save_path: /var/lib/php/sessions)

Filename: Unknown

Line Number: 0

Backtrace: